- Home
- NIVF vs SHPH Comparison
NIVF vs SHPH Comparison
Compare NIVF & SHPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NIVF
- SHPH
- Stock Information
- Founded
- NIVF 2011
- SHPH 2012
- Country
- NIVF Hong Kong
- SHPH United States
- Employees
- NIVF N/A
- SHPH N/A
- Industry
- NIVF
- SHPH Biotechnology: Pharmaceutical Preparations
- Sector
- NIVF
- SHPH Health Care
- Exchange
- NIVF NYSE
- SHPH Nasdaq
- Market Cap
- NIVF 2.1M
- SHPH 2.3M
- IPO Year
- NIVF N/A
- SHPH 2022
- Fundamental
- Price
- NIVF $3.38
- SHPH $0.23
- Analyst Decision
- NIVF
- SHPH
- Analyst Count
- NIVF 0
- SHPH 0
- Target Price
- NIVF N/A
- SHPH N/A
- AVG Volume (30 Days)
- NIVF 351.5K
- SHPH 10.7M
- Earning Date
- NIVF 01-01-0001
- SHPH 05-16-2025
- Dividend Yield
- NIVF N/A
- SHPH N/A
- EPS Growth
- NIVF N/A
- SHPH N/A
- EPS
- NIVF N/A
- SHPH N/A
- Revenue
- NIVF $5,433,375.00
- SHPH N/A
- Revenue This Year
- NIVF N/A
- SHPH N/A
- Revenue Next Year
- NIVF N/A
- SHPH N/A
- P/E Ratio
- NIVF N/A
- SHPH N/A
- Revenue Growth
- NIVF 5.79
- SHPH N/A
- 52 Week Low
- NIVF $1.09
- SHPH $0.23
- 52 Week High
- NIVF $32.80
- SHPH $4.71
- Technical
- Relative Strength Index (RSI)
- NIVF 40.15
- SHPH 32.28
- Support Level
- NIVF $2.82
- SHPH $0.25
- Resistance Level
- NIVF $4.96
- SHPH $0.32
- Average True Range (ATR)
- NIVF 0.80
- SHPH 0.05
- MACD
- NIVF 0.30
- SHPH 0.00
- Stochastic Oscillator
- NIVF 33.61
- SHPH 9.22
About NIVF NEWGENIVF GROUP LIMITED
NewGenIvf Group Ltd is a company engaged in providing assisted reproductive services in Asia Pacific with a focus on providing fertility treatments to fulfil the dreams of building families, NewGenIvf mainly offers two services, namely first which is a in-vitro fertilization (IVF) treatment service, comprising traditional IVF and egg donation; and surrogacy and ancillary caring services.
About SHPH Shuttle Pharmaceuticals Holdings Inc.
Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. It is developing a pipeline of products designed to address the limitations of the current cancer therapies as well as to extend to the new applications of RT. The company believes that its product candidates will enable the company to deliver cancer treatments that are safer, more reliable and at a greater scale than that of the current standard of care.